Abstract: 3-amino-5-carbonylchromans, as well as enantiomers and salts thereof are disclosed. Pharmaceutical compositions containing the compounds as active ingredients are also disclosed. The compounds are useful in the treatment of 5-hydroxytryptamine-mediated disorders of the central nervous system.

Abstract: A method is disclosed for the treatment of anxiety by the administration of 3-amino-5-carbamoyl-chromans and 8-fluoro-3-amino-5-carbamoylchromans or enantiomers or salts thereof.

Abstract: Compounds of the formula ##STR1## are disclosed. These compounds are employed as intermediates in the synthesis of aminochroman compounds useful in the treatment of CNS disorders.

Abstract: A method is disclosed for the treatment of depression by the administration of 3-amino-5-carbamoylchromans and 8-fluoro-3-amino-5-carbamoylchromans or enantiomers or salts thereof.

Abstract: 3-amino-5-aryl- and 5-heteroarylchromans, as well as enantiomers and salts thereof are disclosed. Pharmaceutical compositions containing the compounds as active ingredients are also disclosed. The compounds are useful in the treatment of 5-hydroxytryptamine-mediated disorders of the central nervous system.

Abstract: A method is disclosed for the treatment of migraine by the administration of 3-amino-5-carbamoyl-chromans and 8-fluoro-3-amino-5-carbamoylchromans or enantiomers or salts thereof.

Abstract: A compound having the formula ##STR1## PROCESSES FOR PREPARING SUCH A COMPOUND, INTERMEDIATES SUCH AS ##STR2## USED IN THE PREPARATION THEREOF WHERE A and B together form a second bond or A is OH and B is H and where Y is a splittable group, and pharmaceutical compositions and a method for the treatment of depression and relief of anxiety.

Abstract: A compound of the formula ##STR1## and pharmaceutically acceptable acid addition salts thereof, in which formula the group R.sup.o is trifluoromethyl.Pharmaceutical compositions containing these compounds are useful for treatment of depressive disorders.

Abstract: Compounds of the formula ##STR1## and pharmaceutically acceptable salts thereof, wherein X and Y are the same or different and each representing a hydrogen atom, a chloro or a methoxy group, n is an integer 0 or 1 and R.sup.1 and R.sup.2 are the same or different and each representing a hydrogen atom or a methyl group; processes for their preparation; pharmaceutical preparations containing at least one of these compounds and the use thereof in the treatment of depressive states.

Abstract: Compounds of the formula ##STR1## and pharmaceutically acceptable salts thereof; processes for their preparation; intermediates useful for their preparation; pharmaceutical preparations containing at least one of these compounds; and the use thereof as a tranquilizing or neuroleptic agent.

Abstract: Compounds having the general formula ##STR1## or pharmaceutically acceptable salts thereof, in which formula R.sup.1 and R.sup.2 are the same or different and each represents a hydrogen atom, a lower alkyl group or a halogen atom, R.sup.3 represents a lower alkyl group or a benzyl group, R.sup.4 represents a hydrogen atom, a lower alkyl group, a benzyl group or a CH.sub.2 CH.sub.2 CH.sub.2 -bridge connected to the phenyl ring in ortho-position relative to the N-substituent, R.sup.5 represents a hydrogen atom or a methyl group and R.sup.6 represents a lower alkyl group, provided that R.sup.1 and/or R.sup.2 represents a lower alkyl group or a halogen atom where R.sup.3 represents a methyl group, R.sup.4 represents a methyl group and R.sup.5 represents a hydrogen atom; methods for the preparation thereof; intermediates useful for their preparation; pharmaceutical preparations containing at least one of these compounds; and the use thereof in the treatment of depressive states and alleviating anxiety.

Abstract: Compounds having the general formula ##STR1## or pharmaceutically acceptable salts thereof, in which formula R.sup.1 and R.sup.2 are the same or different and each represents a hydrogen atom, a lower alkyl group or a halogen atom, R.sup.3 represents a lower alkyl group or a benzyl group, R.sup.4 represents a hydrogen atom, a lower alkyl group, a benzyl group or a CH.sub.2 CH.sub.2 CH.sub.2 --bridge connected to the phenyl ring in ortho-position relative to the N-substituent, R.sup.5 represents a hydrogen atom or a methyl group and R.sup.6 represents a lower alkyl group, provided that R.sup.1 and/or R.sup.2 represents a lower alkyl group or a halogen atom when R.sup.3 represents a methyl group, R.sup.4 represents a methyl group and R.sup.5 represents a hydrogen atom; methods for the preparation thereof; intermediates useful for their preparation; pharmaceutical preparations containing at least one of these compounds; and the use thereof in the treatment of depressive states and alleviating anxiety.